Citius Pharmaceuticals to Present at the 11th Annual LD Micro Main Event

CRANFORD, N.J., Nov. 30, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that its Executive Chairman, Leonard Mazur, will present at the 11th Annual LD Micro Main Event. The conference will be held on December 4-6, 2018 at the Luxe Sunset Blvd Hotel, Los Angeles.

Event: 11th Annual LD Micro Main Event
Location: Luxe Sunset Blvd Hotel, Los Angeles
Date: December 4, 2018 – 12:00PM PST

During the conference, Executive Chairman, Mr. Leonard Mazur will deliver the Company's corporate presentation and discuss recent business highlights. Management will also be available for one-on-one meetings. To arrange a meeting with management, please contact Mr. Andrew Scott:

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. 

What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

In 2015, LD Micro launched as a portal to provide exclusive intraday information on the entire sector, including the first pure micro-cap index (LDMi) which covers stocks in North America with market capitalizations between $50 million to $300 million.

About Citius Pharmaceuticals, Inc.

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit


Andrew Scott                                                              
Vice President, Corporate Development                                                       
(o) 908-967-6677


Cision View original content:

SOURCE Citius Pharmaceuticals, Inc.